Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Natalia Gaibu"'
Autor:
Jin Yong Kim, Oana Săndulescu, Liliana-Lucia Preotescu, Norma E Rivera-Martínez, Marta Dobryanska, Victoria Birlutiu, Egidia G Miftode, Natalia Gaibu, Olga Caliman-Sturdza, Simin-Aysel Florescu, Hye Jin Shi, Anca Streinu-Cercel, Adrian Streinu-Cercel, Sang Joon Lee, Sung Hyun Kim, Ilsung Chang, Yun Ju Bae, Jee Hye Suh, Da Rae Chung, Sun Jung Kim, Mi Rim Kim, Seul Gi Lee, Gahee Park, Joong Sik Eom
Publikováno v:
Open forum infectious diseases. 9(8)
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease progression and clinical recovery time in patients with mild-to-moderate c
Autor:
Michael G Ison, Jin Yong Kim, Oana Sandulescu, Liliana-Lucia Preotescu, Norma Erendira Rivera Martinez, Marta Dobryanska, Victoria Birlutiu, Egidia Gabriela Miftode, Natalia Gaibu, Olga Adriana Caliman-Sturdza, Simin-Aysel Florescu, Anca Streinu-Cercel, Sang Joon Lee, Sung Hyun Kim, Il Sung Chang, Yun Ju Bae, Jee Hye Suh, Mi Rim Kim, Da Re Chung, Sun Jung Kim, Seul Gi Lee, Ga Hee Park, Joong Sik Eom
Publikováno v:
Open Forum Infectious Diseases
Background Regdanvimab is a monoclonal antibody with activity against SARS-CoV-2. A Phase 2/3 study with two parts is currently ongoing and data up to Day 28 of Part 1 is available while the data from 1315 patients enrolled in Part 2 are expected in
Autor:
Ronald B. Langdon, Ying Guo, Eunkyung Kauh, Serghei Popa, Natalia Gaibu, Daniel Tatosian, Andrea K. Schaeffer, Aubrey Stoch
Publikováno v:
Diabetes Therapy
Introduction Saxagliptin, sitagliptin, and vildagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors widely approved for use in patients with type 2 diabetes. Using a crossover design, the present study compared trough levels of DPP-4 inhibition pro